These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36545453)

  • 61. Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline.
    Hung AM; Roumie CL; Greevy RA; Grijalva CG; Liu X; Murff HJ; Ikizler TA; Griffin MR
    Clin J Am Soc Nephrol; 2016 Dec; 11(12):2177-2185. PubMed ID: 27827311
    [TBL] [Abstract][Full Text] [Related]  

  • 62. An analysis of the relative risk for goitre in euthyroid patients with type 2 diabetes.
    Díez JJ; Iglesias P
    Clin Endocrinol (Oxf); 2014 Mar; 80(3):356-61. PubMed ID: 23414115
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
    Bowker SL; Majumdar SR; Veugelers P; Johnson JA
    Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Avilés-Santa L; Sinding J; Raskin P
    Ann Intern Med; 1999 Aug; 131(3):182-8. PubMed ID: 10428734
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
    Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
    Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.
    Jil M; Rajnikant M; Richard D; Iskandar I
    Diab Vasc Dis Res; 2017 Jul; 14(4):295-303. PubMed ID: 28330386
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Benefits of metformin add-on insulin therapy (MAIT) for HbA1c and lipid profile in adolescents with type 1 diabetes mellitus: preliminary report from a double-blinded, placebo-controlled, randomized clinical trial.
    Sheikhy A; Eydian Z; Fallahzadeh A; Shakiba M; Hajipour M; Alaei M; Mosallanejad A; Saneifard H
    J Pediatr Endocrinol Metab; 2022 Apr; 35(4):505-510. PubMed ID: 35249270
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients.
    Hermann LS; Kalén J; Katzman P; Lager I; Nilsson A; Norrhamn O; Sartor G; Ugander L
    Diabetes Obes Metab; 2001 Dec; 3(6):428-34. PubMed ID: 11903415
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The Usefulness of Diagnostic Panels Based on Circulating Adipocytokines/Regulatory Peptides, Renal Function Tests, Insulin Resistance Indicators and Lipid-Carbohydrate Metabolism Parameters in Diagnosis and Prognosis of Type 2 Diabetes Mellitus with Obesity.
    Komosinska-Vassev K; Gala O; Olczyk K; Jura-Półtorak A; Olczyk P
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32917052
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation.
    Shestakova MV; Vikulova OK; Elfimova AR; Deviatkin AA; Dedov II; Mokrysheva NG
    Front Endocrinol (Lausanne); 2022; 13():909874. PubMed ID: 36017317
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus.
    Simons WR; Hagan MA
    Pharmacoeconomics; 2010; 28(9):765-80. PubMed ID: 20799756
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Metformin in peritoneal dialysis: a pilot experience.
    Al-Hwiesh AK; Abdul-Rahman IS; El-Deen MA; Larbi E; Divino-Filho JC; Al-Mohanna FA; Gupta KL
    Perit Dial Int; 2014 Jun; 34(4):368-75. PubMed ID: 24584596
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses.
    Hemmingsen B; Christensen LL; Wetterslev J; Vaag A; Gluud C; Lund SS; Almdal T
    BMJ; 2012 Apr; 344():e1771. PubMed ID: 22517929
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy.
    Mirani M; Favacchio G; Carrone F; Betella N; Biamonte E; Morenghi E; Mazziotti G; Lania AG
    Diabetes Care; 2020 Dec; 43(12):3042-3049. PubMed ID: 33023989
    [TBL] [Abstract][Full Text] [Related]  

  • 75. COVID-19 outcomes in patients taking cardioprotective medications.
    Morrison FJ; Su M; Turchin A
    PLoS One; 2022; 17(10):e0275787. PubMed ID: 36215288
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study.
    Hanefeld M; Pfützner A; Forst T; Kleine I; Fuchs W
    Cardiovasc Diabetol; 2011 Jul; 10():65. PubMed ID: 21756323
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Rationale, design, and methods for the Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD) study.
    Berry DC; Thomas SD; Dorman KF; Ivins AR; de Los Angeles Abreu M; Young L; Boggess K
    BMC Pregnancy Childbirth; 2018 Dec; 18(1):488. PubMed ID: 30541506
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The excess insulin requirement in severe COVID-19 compared to non-COVID-19 viral pneumonitis is related to the severity of respiratory failure and pre-existing diabetes.
    Lockhart SM; Griffiths H; Petrisor B; Usman A; Calvo-Latorre J; Heales L; Bansiya V; Mahroof R; Conway Morris A
    Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00228. PubMed ID: 34268452
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury.
    Chen X; Guo H; Qiu L; Zhang C; Deng Q; Leng Q
    Front Immunol; 2020; 11():2056. PubMed ID: 32973814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.